Metabolic profile evolution in relapsed/refractory B-cell non-Hodgkin lymphoma patients treated with CD19 chimeric antigen receptor T-cell therapy and implications in clinical outcome.

Haematologica · 2025 · PMC12208157 · PMID 39704157

Europe PMC DOI

hedged sentence

0.0760

closest p · 1.5× alpha

0.0760

boldest claim

The sentences

showed a trendP =0.076so close (0.05 < p ≤ 0.1)

This approach gave us the possibility to calculate the GlycoAge 10 score which, in our case series, was positively correlated with CRP (r=0.58; P =0.01) and that showed a trend towards higher levels ( P =0.076) in patients who relapsed at 3 or 6 months compared to those who remained in CR up to 6 months ( Online Supplementary Figure S4 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.